Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2022 07:01 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
November 01, 2022 17:38 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
October 24, 2022 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

NEW YORK and SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
October 17, 2022 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

NEW YORK and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
October 03, 2022 17:32 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
September 27, 2022 16:01 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer

NEW YORK and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
September 19, 2022 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer

NEW YORK and SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
September 12, 2022 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors

NEW YORK and SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing...
September 01, 2022 17:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
August 31, 2022 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

NEW YORK and SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right